Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
Cancers (Basel). 2022 Sep 20;14(19):4566. doi: 10.3390/cancers14194566.
Cancers (Basel). 2022.
PMID: 36230489
Free PMC article.
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
Gerner B, et al. Among authors: aghai trommeschlaeger f.
Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556.
Pharmaceutics. 2022.
PMID: 36559050
Free PMC article.
Item in Clipboard
Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Aghai-Trommeschlaeger F, Zimmermann S, Gesierich A, Kalogirou C, Goebeler ME, Jung P, Pelzer T, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
Aghai-Trommeschlaeger F, et al.
Clin Biochem. 2022 Jul-Aug;105-106:35-43. doi: 10.1016/j.clinbiochem.2022.04.011. Epub 2022 Apr 26.
Clin Biochem. 2022.
PMID: 35483452
Item in Clipboard
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
Zimmermann S, et al. Among authors: aghai trommeschlaeger f.
J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311. Epub 2023 Feb 23.
J Pharm Biomed Anal. 2023.
PMID: 36841066
Item in Clipboard
Cite
Cite